Abstract
The treatment of persistent asthma has been aided by the recent approval of new medications. The combined inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) powder inhaler fluticasone furoate (FF)/vilanterol trifenatate (VI) is one of these new agents, which was recently approved as a maintenance therapy for persistent asthma. This once-daily ICS/LABA inhaler has previously been approved and used in chronic obstructive pulmonary disease as a maintenance therapy. Both FF and VI individually have been shown to have efficacy in the treatment of persistent asthma; the combination of FF/VI at the dose of 100/25 Î1/4g daily improves trough peak expiratory flows and forced expiratory volume in 1 s. It also reduces the frequency of asthma exacerbations in patients with persistent asthma. The once-daily dosing is well tolerated, with limited clinically significant adverse events; the once-daily inhaled dosing regimen should also improve medication adherence. The data supporting the use of the FF/VI inhaler in persistent asthma are reviewed. The dry powder inhaler of FF/VI (100/25 Î1/4g) is an effective and well tolerated once-daily maintenance treatment for patients with persistent asthma.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 43-56 |
| Number of pages | 14 |
| Journal | Therapeutic Advances in Respiratory Disease |
| Volume | 10 |
| Issue number | 1 |
| DOIs | |
| State | Published - Feb 1 2016 |
Fingerprint
Keywords
- combined inhaler
- fluticasone furoate/vilanterol trifenatate
- inhaled corticosteroid
- long-acting β2 agonist
- persistent asthma
- powder inhaler
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
- Pharmacology (medical)
Cite this
The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma : Clinical trial evidence and experience. / Albertson, Timothy E; Richards, John R; Zeki, Amir.
In: Therapeutic Advances in Respiratory Disease, Vol. 10, No. 1, 01.02.2016, p. 43-56.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma
T2 - Clinical trial evidence and experience
AU - Albertson, Timothy E
AU - Richards, John R
AU - Zeki, Amir
PY - 2016/2/1
Y1 - 2016/2/1
N2 - The treatment of persistent asthma has been aided by the recent approval of new medications. The combined inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) powder inhaler fluticasone furoate (FF)/vilanterol trifenatate (VI) is one of these new agents, which was recently approved as a maintenance therapy for persistent asthma. This once-daily ICS/LABA inhaler has previously been approved and used in chronic obstructive pulmonary disease as a maintenance therapy. Both FF and VI individually have been shown to have efficacy in the treatment of persistent asthma; the combination of FF/VI at the dose of 100/25 Î1/4g daily improves trough peak expiratory flows and forced expiratory volume in 1 s. It also reduces the frequency of asthma exacerbations in patients with persistent asthma. The once-daily dosing is well tolerated, with limited clinically significant adverse events; the once-daily inhaled dosing regimen should also improve medication adherence. The data supporting the use of the FF/VI inhaler in persistent asthma are reviewed. The dry powder inhaler of FF/VI (100/25 Î1/4g) is an effective and well tolerated once-daily maintenance treatment for patients with persistent asthma.
AB - The treatment of persistent asthma has been aided by the recent approval of new medications. The combined inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) powder inhaler fluticasone furoate (FF)/vilanterol trifenatate (VI) is one of these new agents, which was recently approved as a maintenance therapy for persistent asthma. This once-daily ICS/LABA inhaler has previously been approved and used in chronic obstructive pulmonary disease as a maintenance therapy. Both FF and VI individually have been shown to have efficacy in the treatment of persistent asthma; the combination of FF/VI at the dose of 100/25 Î1/4g daily improves trough peak expiratory flows and forced expiratory volume in 1 s. It also reduces the frequency of asthma exacerbations in patients with persistent asthma. The once-daily dosing is well tolerated, with limited clinically significant adverse events; the once-daily inhaled dosing regimen should also improve medication adherence. The data supporting the use of the FF/VI inhaler in persistent asthma are reviewed. The dry powder inhaler of FF/VI (100/25 Î1/4g) is an effective and well tolerated once-daily maintenance treatment for patients with persistent asthma.
KW - combined inhaler
KW - fluticasone furoate/vilanterol trifenatate
KW - inhaled corticosteroid
KW - long-acting β2 agonist
KW - persistent asthma
KW - powder inhaler
UR - http://www.scopus.com/inward/record.url?scp=84957593209&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84957593209&partnerID=8YFLogxK
U2 - 10.1177/1753465815619136
DO - 10.1177/1753465815619136
M3 - Review article
C2 - 26668137
AN - SCOPUS:84957593209
VL - 10
SP - 43
EP - 56
JO - Therapeutic Advances in Respiratory Disease
JF - Therapeutic Advances in Respiratory Disease
SN - 1753-4658
IS - 1
ER -